An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Summary: SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-2-S) in animals, which has advanced to human t...

Full description

Bibliographic Details
Main Authors: Ahmed O. Hassan, Swathi Shrihari, Matthew J. Gorman, Baoling Ying, Dansu Yaun, Saravanan Raju, Rita E. Chen, Igor P. Dmitriev, Elena Kashentseva, Lucas J. Adams, Colin Mann, Meredith E. Davis-Gardner, Mehul S. Suthar, Pei-Yong Shi, Erica Ollmann Saphire, Daved H. Fremont, David T. Curiel, Galit Alter, Michael S. Diamond
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Cell Reports
Subjects:
SARS-CoV-2
COVID-19
vaccine
mucosal immunity
durability
antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S221112472100869X

Internet

http://www.sciencedirect.com/science/article/pii/S221112472100869X

Similar Items